| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
Janus green B does not have a specific pharmacological target. Its primary target is mitochondria, where it is reduced by the activity of the electron transport chain. The dye's staining is oxygen-dependent and reversibly inhibited by cyanide, indicating that its reduction is linked to mitochondrial respiration. It also interacts with DNA. In histology, it is used as a vital stain to assess mitochondrial function and integrity in living cells.
|
|---|---|
| ln Vitro |
Janus green B does not have specific in vitro activity in the context of drug development. Its activity is as a histological stain. In vitro, it is used to stain mitochondria in cultured cells. Cells are incubated with the dye, and the staining pattern is observed under a light microscope. Healthy mitochondria reduce the dye to a pink or colorless form, while damaged mitochondria remain blue-green. This assay is used to assess mitochondrial function and cell viability.
|
| ln Vivo |
Janus green B is not a drug and is not administered for therapeutic purposes in vivo. However, it has been used in vivo for staining purposes in research. For example, it has been used to stain peripheral nerves in live insects and lymphatic vessels in rabbits. In these applications, the dye is applied topically or injected, and the staining is observed under a microscope. It is not used in disease models for therapeutic evaluation.
|
| Enzyme Assay |
Non-cellular in vitro assays for Janus green B are not applicable, as it is a histological stain and not a biochemical inhibitor. However, its staining properties can be characterized spectrophotometrically. For example, its absorbance maximum (lambda max) can be measured in methanol, which is typically around 650 ± 10 nm. Its purity and dye content can be determined by HPLC.
|
| Cell Assay |
Cellular assays for Janus green B are performed to assess mitochondrial function. A typical protocol involves incubating cells with Janus green B at a concentration of 0.01-0.001% in a culture medium for 10-30 minutes at 37°C. The cells are then washed and observed under a light microscope. The number of cells with stained mitochondria is counted. The intensity of staining can be used as an indicator of mitochondrial activity. This assay is used to assess the effects of drugs or toxins on mitochondrial function.
|
| Animal Protocol |
In vivo animal studies for Janus green B are limited to staining applications. For example, it has been used to stain peripheral nerves in live insects. In these studies, the dye is applied to the exposed nerve, and the staining is observed under a microscope. It has also been used to stain lymphatic vessels in rabbits. These studies are primarily for anatomical or physiological research, not for evaluating therapeutic efficacy.
|
| ADME/Pharmacokinetics |
Janus green B is a dye and does not have pharmacokinetic properties in the context of drug development. When used for staining, it is applied locally and is not intended for systemic absorption. Its solubility in water (20 mg/ml at 20°C) and ethanol makes it suitable for use in aqueous and alcoholic staining solutions.
|
| Toxicity/Toxicokinetics |
Janus green B is a histological dye and is not intended for human therapeutic use. Its toxicity is not extensively characterized, but as a dye, it is not meant for internal use. Standard laboratory safety precautions should be followed when handling it, including the use of gloves and working in a well-ventilated area. It should be stored away from oxidizing agents in a cool, dry, and well-ventilated condition.
|
| References |
|
| Additional Infomation |
Jenners Green B chloride is an organochloride salt used as a dye and contains the Jenners Green B cation.
Janus green B is a well-known histological stain that has been used for over a century. It is a supravital stain, meaning it can stain living cells without killing them. Its ability to stain mitochondria is based on the reduction of the dye by the electron transport chain, making it a useful tool for studying mitochondrial function and integrity. It has been used in studies of mitochondrial pathology, cell viability, and neuroanatomy. It is not a drug and has no clinical trial or regulatory approval status. Its primary value is as a research tool in histology and cell biology. |
| Molecular Formula |
C30H31CLN6
|
|---|---|
| Molecular Weight |
511.0603
|
| Exact Mass |
510.229
|
| CAS # |
2869-83-2
|
| PubChem CID |
76123
|
| Appearance |
Brown to black solid powder
|
| Melting Point |
160 °C (dec.)(lit.)
|
| Vapour Pressure |
2.6 mm Hg ( 20 °C)
|
| LogP |
3.996
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
37
|
| Complexity |
694
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Cl-].[N+]1(C2C([H])=C([H])C([H])=C([H])C=2[H])C2C([H])=C(C([H])=C([H])C=2N=C2C([H])=C([H])C(=C([H])C=12)N(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])[H])/N=N/C1C([H])=C([H])C(=C([H])C=1[H])N(C([H])([H])[H])C([H])([H])[H]
|
| InChi Key |
XXACTDWGHQXLGW-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C30H31N6.ClH/c1-5-35(6-2)26-17-19-28-30(21-26)36(25-10-8-7-9-11-25)29-20-23(14-18-27(29)31-28)33-32-22-12-15-24(16-13-22)34(3)4;/h7-21H,5-6H2,1-4H3;1H/q+1;/p-1
|
| Chemical Name |
8-[[4-(dimethylamino)phenyl]diazenyl]-N,N-diethyl-10-phenylphenazin-10-ium-2-amine;chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~244.59 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9567 mL | 9.7836 mL | 19.5672 mL | |
| 5 mM | 0.3913 mL | 1.9567 mL | 3.9134 mL | |
| 10 mM | 0.1957 mL | 0.9784 mL | 1.9567 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05610163 | RECRUITING | Drug: Capecitabine Drug: 5-fluorouracil Drug: Leucovorin calcium |
Locally Advanced Rectal Carcinoma Stage II Rectal Cancer AJCC v8 Stage III Rectal Cancer AJCC v8 |
Alliance for Clinical Trials in Oncology | 2022-12-08 | Phase 2 |
| NCT03970837 | TERMINATEDWITH RESULTS | Biological: GSK3196165 (Otilimab) Drug: Tofacitinib Drug: Placebo |
Arthritis, Rheumatoid | GlaxoSmithKline | 2019-06-05 | Phase 3 |
| NCT03104400 | ACTIVE, NOT RECRUITINGWITH RESULTS | Drug: Adalimumab Drug: Upadacitinib Drug: Placebo to Upadacitinib Drug: Placebo to Adalimumab |
Psoriatic Arthritis | AbbVie | 2017-04-27 | Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
